These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36028955)

  • 21. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the Increase in Bone Mineral Density After Surgical Treatment of Primary Hyperparathyroidism.
    Mendoza-Moreno F; Díez-Alonso M; Ovejero-Merino E; Sánchez-Gollarte A; Alvarado-Hurtado R; Matías-García B; Rodríguez-Pascual Á; Medina-Reinoso C; Ratia-Jiménez T; Hernández-Merlo F; Granell-Vicent J
    J Clin Densitom; 2019; 22(2):171-178. PubMed ID: 30482495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Handgrip strength as a predictor of bone mineral density in outpatients with cirrhosis.
    Santos LA; Lima TB; Augusti L; Franzoni Lde C; Yamashiro Fda S; Bolfi F; Nunes Vdos S; Dorna Mde S; de Oliveira CV; Caramori CA; Silva GF; Romeiro FG
    J Gastroenterol Hepatol; 2016 Jan; 31(1):229-34. PubMed ID: 26212461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet.
    Fiore CE; Pennisi P; Ferro G; Ximenes B; Privitelli L; Mangiafico RA; Santoro F; Parisi N; Lombardo T
    Horm Metab Res; 2006 Jun; 38(6):417-22. PubMed ID: 16823725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Receptor Activator of Nuclear Factor κ-Β Ligand/Osteoprotegerin Axis in Adults with Hb S/β-Thalassemia and β-Thalassemia Trait.
    Tombak A; Boztepe B; Akbayir S; Dogru G; Sungur MA
    Hemoglobin; 2020 Sep; 44(5):334-337. PubMed ID: 32873083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone mineral density assessed by dual-energy X-ray absorptiometry in patients with viral or alcoholic compensated cirrhosis. A prospective study.
    Mahmoudi A; Sellier N; Reboul-Marty J; Chalès G; Lalatonne Y; Bourcier V; Grando V; Barget N; Beaugrand M; Trinchet JC; Ganne-Carrié N
    Clin Res Hepatol Gastroenterol; 2011 Nov; 35(11):731-7. PubMed ID: 21873139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
    Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
    BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone mineral density in patients with pancreatic insufficiency and steatorrhea.
    Morán CE; Sosa EG; Martinez SM; Geldern P; Messina D; Russo A; Boerr L; Bai JC
    Am J Gastroenterol; 1997 May; 92(5):867-71. PubMed ID: 9149203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D status & bone health in patients with liver cirrhosis.
    Grover I; Singh N; Gunjan D; Benjamin J; Ramakrishnan L; Pandey RM; Sati HC; Saraya A
    Indian J Med Res; 2023 Sep; 158(3):284-291. PubMed ID: 37815065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
    Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
    Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study.
    Zhang W; Gong H; Su Z; Zhang X; Cao S
    Medicine (Baltimore); 2019 Aug; 98(31):e16628. PubMed ID: 31374030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.
    Moldovan D; Rusu C; Potra A; Moldovan I; Patiu IM; Gherman-Caprioara M; Kacso IM
    Int Urol Nephrol; 2017 May; 49(5):895-901. PubMed ID: 28161839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
    Franck H; Meurer T; Hofbauer LC
    J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.
    Oelzner P; Franke S; Lehmann G; Eidner T; Müller A; Wolf G; Hein G
    Clin Rheumatol; 2007 Dec; 26(12):2127-2135. PubMed ID: 17541498
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
    Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
    J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A study of osteopenia in liver cirrhosis by dual energy X-ray absorptiometry (DXA)].
    Nakano A; Kanda T; Miyamoto T; Ishigami Y; Sato T; Shimizu Y
    Nihon Shokakibyo Gakkai Zasshi; 1993 Aug; 90(8):1689-94. PubMed ID: 8361060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone Metabolism and the c.-223C > T Polymorphism in the 5'UTR Region of the Osteoprotegerin Gene in Patients with Inflammatory Bowel Disease.
    Krela-Kaźmierczak I; Kaczmarek-Ryś M; Szymczak A; Michalak M; Skrzypczak-Zielińska M; Drwęska-Matelska N; Marcinkowska M; Eder P; Łykowska-Szuber L; Wysocka E; Linke K; Słomski R
    Calcif Tissue Int; 2016 Dec; 99(6):616-624. PubMed ID: 27639566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cirrhosis on bone mineral density and bone metabolism.
    Turkeli M; Dursun H; Albayrak F; Okçu N; Uyanik MH; Uyanik A; Yıldırım R; Keleş M; Yılmaz O
    Eurasian J Med; 2008 Apr; 40(1):18-24. PubMed ID: 25610017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction.
    Figueiredo FA; Brandão C; Perez Rde M; Barbosa WF; Kondo M
    Arq Gastroenterol; 2003; 40(3):152-8. PubMed ID: 15029390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.